GlassScriptPhysician profile
Stephanie Danielle Black
NPI 1386169126
$6,869.18
in general payments reported to CMS, 2019-2025
28 companies · $3,384 in 2025
The $3,384 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $35.27 · 2024: $3,449 · 2025: $3,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,668 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,668.24 |
| Education | $200.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,066.00 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $993.87 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $968.39 | 2024-2025 | |
| Lilly USA, LLC | $497.26 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $348.25 | 2024-2025 | Ibsrela |
| Pfizer INC. | $346.61 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $339.59 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.30 | 2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $279.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $199.88 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $181.47 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $181.04 | 2024-2025 | Epclusa |
| Qol Medical, LLC | $160.35 | 2024-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $149.26 | 2024-2025 | Injectafer |
| Shield Therapeutics INC | $129.19 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $102.48 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $101.74 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $89.06 | 2025 | Monoferric |
| Celltrion USA INC. | $86.95 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Scientific Affairs, LLC | $81.57 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $53.97 | 2024 | Dificid, Zinplava |
| Celgene Corporation | $36.47 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $35.78 | 2025 | Iqirvo |
| Innovation Technologies INC | $35.27 | 2023 | Irrisept |
| Ironwood Pharmaceuticals, INC | $21.27 | 2024 | |
| Sandoz INC. | $20.16 | 2024 | Hyrimoz |
| Hydrofera LLC | $16.50 | 2024 | Hydrofera Blue |
| Organon LLC | $16.34 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.